Fennec Pharmaceuticals Inc
NASDAQ:FENC
Fennec Pharmaceuticals Inc
Revenue
Fennec Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
F
|
Fennec Pharmaceuticals Inc
NASDAQ:FENC
|
Revenue
$21.3m
|
CAGR 3-Years
400%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Fennec Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Fennec Pharmaceuticals Inc
Breakdown by Segments
Fennec Pharmaceuticals Inc
Total Revenue:
21.3m
USD
|
Information Relating To Pedmark:
21.3m
USD
|
See Also
What is Fennec Pharmaceuticals Inc's Revenue?
Revenue
21.3m
USD
Based on the financial report for Dec 31, 2023, Fennec Pharmaceuticals Inc's Revenue amounts to 21.3m USD.
What is Fennec Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 3Y
400%
Over the last year, the Revenue growth was 1 280%. The average annual Revenue growth rates for Fennec Pharmaceuticals Inc have been 400% over the past three years .